Serum erythropoietin level predicts the prognosis of chronic heart failure with or without anemia

Guo,Ling; Wang,Ai-Hong; Sun,Yong-Le; Lv,Lin; Xu,Chong-En

doi:10.3892/etm.2013.1307

Serum erythropoietin level predicts the prognosis of chronic heart failure with or without anemia

Authors:
- Ling Guo
- Ai-Hong Wang
- Yong-Le Sun
- Lin Lv
- Chong-En Xu
View Affiliations

Affiliations: Department of Cardiology, Provincial Hospital Affiliated to Shandong University, Jinan, Shandong 250021, P.R China, Department of Cardiac Surgery, Provincial Hospital Affiliated to Shandong University, Jinan, Shandong 250021, P.R China
Published online on: September 18, 2013 https://doi.org/10.3892/etm.2013.1307
Pages: 1327-1331

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of this study was to explore the correlation of erythropoietin (EPO) with N-terminal pro-B-type natriuretic peptide (NT-proBNP) and high sensitivity C-reactive protein (hs-CRP) in patients with chronic heart failure (CHF) or CHF complicated with anemia, in addition to its correlation with the prognosis of the patient. A total of 217 CHF patients were enrolled in this study. The patients were graded according to the cardiac function criteria of the New York Heart Association (NYHA). The serum EPO, NT-proBNP and hs-CRP levels of the patients were determined. The patients were followed up for ≥24 months. The EPO expression level in patients with NYHA II-IV CHF was significantly higher compared with that in the control group (P<0.05). EPO expression increased with the aggravation of CHF, exhibiting significant differences amongst the various NYHA graded groups (P<0.05). The EPO expression level increased significantly with an increase in NHA grade in addition to the severity of the anemia in the patients with CHF complicated by anemia (P<0.05). In the patients who succumbed (mortality group), the expression level of EPO was significantly higher and the hemoglobin level was significantly lower compared with those of the survival group (P<0.05). The EPO expression levels were elevated in CHF patients and patients with CHF and anemia. The level of expression correlated positively with the severity of CHF as well as that of anemia. Serum EPO measurements were successful in predicting the mortality and re-hospitalization rates of CHF patients at the end point, within two years of follow-up.

View Figures

View References

1.	Levy D, Kenchaiah S, Larson MG, et al: Long-term trends in the incidence of and survival with heart failure. N Engl J Med. 347:1397–1402. 2002. View Article : Google Scholar : PubMed/NCBI
2.	Roger VL, Weston SA, Redfield MM, et al: Trends in heart failure incidence and survival in a community-based population. JAMA. 292:344–350. 2004. View Article : Google Scholar : PubMed/NCBI
3.	Agarwal AK and Katz SD: Future directions in management of anemia in heart failure. Heart Fail Clin. 6:385–395. 2010.PubMed/NCBI
4.	Tang WH, Tong W, Jain A, et al: Evaluation and long-term prognosis of new-onset, transient, and persistent anemia in ambulatory patients with chronic heart failure. J Am Coll Cardiol. 51:569–576. 2008. View Article : Google Scholar : PubMed/NCBI
5.	Anand IS, Kuskowski MA, Rector TS, et al: Anemia and change in hemoglobin over time related to mortality and morbidity in patients with chronic heart failure: results from Val-HeFT. Circulation. 112:1121–1127. 2005. View Article : Google Scholar : PubMed/NCBI
6.	O’Meara E, Clayton T, McEntegart MB, et al CHARM Committees and Investigators: Clinical correlates and consequences of anemia in a broad spectrum of patients with heart failure: results of the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) Program. Circulation. 113:986–994. 2006.
7.	Young JB, Abraham WT, Albert NM, et al OPTIMIZE-HF Investigators and Coordinators: Relation of low hemoglobin and anemia to morbidity and mortality in patients hospitalized with heart failure (insight from the OPTIMIZE-HF registry). Am J Cardiol. 101:223–230. 2008. View Article : Google Scholar : PubMed/NCBI
8.	Bansal N, Tighiouart H, Weiner D, et al: Anemia as a risk factor for kidney function decline in individuals with heart failure. Am J Cardiol. 99:1137–1142. 2007. View Article : Google Scholar : PubMed/NCBI
9.	Felker GM, Adams KF Jr, Gattis WA and O’Connor CM: Anemia as a risk factor and therapeutic target in heart failure. J Am Coll Cardiol. 44:959–966. 2004. View Article : Google Scholar : PubMed/NCBI
10.	Caramelo C, Justo S and Gil P: Anemia in heart failure: pathophysiology, pathogenesis, treatment, and incognitae. Rev Esp Cardiol. 60:848–860. 2007.(In Spanish).
11.	Terrovitis JV, Anastasiou-Nana M, Kaldara E, Drakos SG, Nanas SN and Nanas JN: Anemia in heart failure: pathophysiologic insights and treatment options. Future Cardiol. 5:71–81. 2009. View Article : Google Scholar : PubMed/NCBI
12.	Belonje AM, de Boer RA and Voors AA: Recombinant human Epo treatment: beneficial in chronic kidney disease, chronic heart failure, or both? Editorial to: “Correction of anemia with erythropoietin in chronic kidney disease (stage 3 or 4): effects on cardiac performance by Pappas et al”. Cardiovasc Drugs Ther. 22:1–2. 2008.
13.	Büyüklü M: Heart failure: erythropoietin in treatment of anemia. Anadolu Kardiyol Derg. 7:342–343. 2007.(In Turkish).
14.	Cohen RS, Karlin P, Yushak M, Mancini D and Maurer MS: The effect of erythropoietin on exercise capacity, left ventricular remodeling, pressure-volume relationships, and quality of life in older patients with anemia and heart failure with preserved ejection fraction. Congest Heart Fail. 16:96–103. 2010.
15.	Kotecha D, Ngo K, Walters JA, Manzano L, Palazzuoli A and Flather MD: Erythropoietin as a treatment of anemia in heart failure: systematic review of randomized trials. Am Heart J. 161:822–831. 2011. View Article : Google Scholar : PubMed/NCBI
16.	Balion C, Santaguida PL, Hill S, et al: Testing for BNP and NT-proBNP in the diagnosis and prognosis of heart failure. Evid Rep Technol Assess (Full Rep). 142:1–147. 2006.PubMed/NCBI
17.	Tsutamoto T, Sakai H, Nishiyama K, et al: Direct comparison of transcardiac increase in brain natriuretic peptide (BNP) and N-terminal proBNP and prognosis in patients with chronic heart failure. Circ J. 71:1873–1878. 2007. View Article : Google Scholar
18.	Yu CM, Fung JW, Zhang Q, et al: Improvement of serum NT-ProBNP predicts improvement in cardiac function and favorable prognosis after cardiac resynchronization therapy for heart failure. J Card Fail. 11:S42–46. 2005. View Article : Google Scholar : PubMed/NCBI
19.	Lupón J, Urrutia A, González B, et al: Prognostic significance of hemoglobin levels in patients with heart failure. Rev Esp Cardiol. 58:48–53. 2005.(In Spanish).
20.	Varadarajan P, Gandhi S, Sharma S, Umakanthan B and Pai RG: Prognostic significance of hemoglobin level in patients with congestive heart failure and normal ejection fraction. Clin Cardiol. 29:444–449. 2006. View Article : Google Scholar : PubMed/NCBI
21.	Akram K and Pearlman BL: Congestive heart failure-related anemia and a role for erythropoietin. Int J Cardiol. 117:296–305. 2007. View Article : Google Scholar : PubMed/NCBI
22.	Ruifrok WP, Qian C, Silljé HH, et al: Heart failure-associated anemia: bone marrow dysfunction and response to erythropoietin. J Mol Med (Berl). 89:377–387. 2011. View Article : Google Scholar : PubMed/NCBI
23.	Timmer SA, De Boer K, Knaapen P, Götte MJ and Van Rossum AC: The potential role of erythropoietin in chronic heart failure: from the correction of anemia to improved perfusion and reduced apoptosis? J Card Fail. 15:353–361. 2009. View Article : Google Scholar : PubMed/NCBI
24.	Ogino A, Takemura G, Kawasaki M, et al: Erythropoietin receptor signaling mitigates renal dysfunction-associated heart failure by mechanisms unrelated to relief of anemia. J Am Coll Cardiol. 56:1949–1958. 2010. View Article : Google Scholar
25.	Palazzuoli A, Silverberg D, Iovine F, et al: Erythropoietin improves anemia exercise tolerance and renal function and reduces B-type natriuretic peptide and hospitalization in patients with heart failure and anemia. Am Heart J. 152:1096. e9–15. 2006.PubMed/NCBI
26.	Tang WH and Yeo PS: Epidemiology of anemia in heart failure. Heart Fail Clin. 6:271–278. 2010. View Article : Google Scholar